<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4312">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264016</url>
  </required_header>
  <id_info>
    <org_study_id>CTD-2010-004-01</org_study_id>
    <nct_id>NCT01264016</nct_id>
  </id_info>
  <brief_title>Performance of a New Glucose Meter System</brief_title>
  <official_title>Performance of the TATSU/Tradewind Blood Glucose Monitoring System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascensia Diabetes Care</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascensia Diabetes Care</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the performance and acceptability of a new blood
      glucose monitoring system, which includes meter and sensor strip.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Percent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (&lt;75 mg/dL) or Within +/- 5% to 20% (&gt;=75 mg/dL) of Laboratory Glucose Method</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects with diabetes used an investigational blood glucose monitoring system (BGMS) with subject capillary blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results &lt;75mg/dL) or +/- 5 to 20% (for reference BG results &gt;=75mg/dL) of the reference method results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (&lt;75 mg/dL) or Within +/- 5% to 20% (&gt;=75 mg/dL) of Laboratory Glucose Method</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Healthcare professionals (study staff) used an investigational blood glucose monitoring system (BGMS) with subject venous blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results &lt;75mg/dL) or +/- 5% to 20% (for reference BG results &gt;=75mg/dL) of the reference method results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Rated as&lt;=3 Performing Basic Meter Tasks (Labeling Comprehension)</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects reviewed the instructions for use (User Guide and Quick Reference Guide) to learn to use the system. Study staff then observed and rated the subjects (1 to 4) on their success at performing five tasks. Scale: 1.Success in performing tasks correctly without assistance. 2.Successful with additional review of User Guide. 3.Successful with additional review and study staff assist similar to review of a specific function during a Customer Service call. 4.Subject did not perform task correctly and study staff intervention was required.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Intended Users of the Monitoring System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Untrained subjects with diabetes use an investigational blood glucose monitoring system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Investigational Blood Glucose Monitoring System</intervention_name>
    <description>Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.</description>
    <arm_group_label>Intended Users of the Monitoring System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 or 2 diabetes

          -  Age 18 years or older

          -  Routinely performs blood glucose self testing at home, at least once per day

          -  Able to speak, read, and understand English.

          -  Is willing to complete all study procedures

        Exclusion Criteria:

          -  Currently pregnant

          -  Hemophilia or any other bleeding disorder

          -  Taking prescription anticoagulants or has clotting problems that may prolong
             bleeding. Taking aspirin daily is not excluded

          -  Subject employee of competitive medical device company

          -  Cognitive disorder or other condition, which in the opinion of the investigator,
             would put the person at risk or seriously compromise the integrity of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Bailey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMCR Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 29, 2016</lastchanged_date>
  <firstreceived_date>December 18, 2010</firstreceived_date>
  <firstreceived_results_date>April 4, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intended Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes use an investigational blood glucose monitoring system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Felt faint at sight of blood</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intended Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes use an investigational blood glucose monitoring system. One subject withdrew voluntarily; one subject was withdrawn. One subject hematocrit measurement was missing so subject data was not evaluable.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="93"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <sub_title>Mean age (range of ages)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37.8" lower_limit="18" upper_limit="73"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>94 subjects completed study; 93 subjects had evaluable blood glucose data as described in outcome measure results</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>One subject withdrew voluntarily; one subject was withdrawn. 94 subjects completed the study.</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="93"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (&lt;75 mg/dL) or Within +/- 5% to 20% (&gt;=75 mg/dL) of Laboratory Glucose Method</title>
        <description>Subjects with diabetes used an investigational blood glucose monitoring system (BGMS) with subject capillary blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results &lt;75mg/dL) or +/- 5 to 20% (for reference BG results &gt;=75mg/dL) of the reference method results.</description>
        <time_frame>2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>One subject did not complete capillary blood testing (low blood sugar) and one subject hematocrit measurement was missing. These subjects' blood test data was not evaluable. Since the remaining 92 subjects tested 2 test strip lots on the BGM system, 2x92(184) tests results were possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes use an investigational blood glucose monitoring system.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of blood glucose test results analyzed</title>
            <units>blood glucose test results</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="184"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (&lt;75 mg/dL) or Within +/- 5% to 20% (&gt;=75 mg/dL) of Laboratory Glucose Method</title>
            <description>Subjects with diabetes used an investigational blood glucose monitoring system (BGMS) with subject capillary blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results &lt;75mg/dL) or +/- 5 to 20% (for reference BG results &gt;=75mg/dL) of the reference method results.</description>
            <units>percentage of BG Results</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>% within 20mg/dL (&lt;75mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 20mg/dL (&gt;=75mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 15mg/dL (&lt;75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 15mg/dL (&gt;=75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 10mg/dL (&lt;75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 10mg/dL (&gt;=75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 5mg/dL (&lt;75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 5mg/dL (&gt;=75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (&lt;75 mg/dL) or Within +/- 5% to 20% (&gt;=75 mg/dL) of Laboratory Glucose Method</title>
        <description>Healthcare professionals (study staff) used an investigational blood glucose monitoring system (BGMS) with subject venous blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results &lt;75mg/dL) or +/- 5% to 20% (for reference BG results &gt;=75mg/dL) of the reference method results.</description>
        <time_frame>2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>One subject's hematocrit measurement was missing, so this subject's blood test data was not evaluable. Since study staff tested each subject's venous blood using 2 lots of test strips, 2x93(or 186) test results were possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Staff Test Subject Venous Blood</title>
            <description>Healthcare professionals (study staff) used an investigational blood glucose monitoring system (BGMS) with subject venous blood.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of venous blood glucose test results analyzed</title>
            <units>venous blood glucose test results</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="186"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (&lt;75 mg/dL) or Within +/- 5% to 20% (&gt;=75 mg/dL) of Laboratory Glucose Method</title>
            <description>Healthcare professionals (study staff) used an investigational blood glucose monitoring system (BGMS) with subject venous blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results &lt;75mg/dL) or +/- 5% to 20% (for reference BG results &gt;=75mg/dL) of the reference method results.</description>
            <units>percentage of venous bg results</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>% within 20mg/dL (&lt;75mg/dL bg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 20mg/dL (&gt;=75mg/dL bg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 15mg/dL (&lt;75mg/dL bg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 15mg/dL (&gt;=75mg/dL bg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 10mg/dL (&lt;75mg/dL bg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 10mg/dL (&gt;=75mg/dL bg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 5mg/dL (&lt;75mg/dL bg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 5mg/dL (&gt;=75mg/dL bg)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Rated as&lt;=3 Performing Basic Meter Tasks (Labeling Comprehension)</title>
        <description>Subjects reviewed the instructions for use (User Guide and Quick Reference Guide) to learn to use the system. Study staff then observed and rated the subjects (1 to 4) on their success at performing five tasks. Scale: 1.Success in performing tasks correctly without assistance. 2.Successful with additional review of User Guide. 3.Successful with additional review and study staff assist similar to review of a specific function during a Customer Service call. 4.Subject did not perform task correctly and study staff intervention was required.</description>
        <time_frame>2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the Monitoring System</title>
            <description>Untrained subjects with diabetes use an investigational blood glucose monitoring system.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Rated as&lt;=3 Performing Basic Meter Tasks (Labeling Comprehension)</title>
            <description>Subjects reviewed the instructions for use (User Guide and Quick Reference Guide) to learn to use the system. Study staff then observed and rated the subjects (1 to 4) on their success at performing five tasks. Scale: 1.Success in performing tasks correctly without assistance. 2.Successful with additional review of User Guide. 3.Successful with additional review and study staff assist similar to review of a specific function during a Customer Service call. 4.Subject did not perform task correctly and study staff intervention was required.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Turn meter on/off</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Date and Time Set on Meter</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Normal Control Testing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Subject blood testing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Understand underfill icon/ability to apply more bl</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each subject participated for approximately 2 hours.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intended Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes use an investigational blood glucose monitoring system.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Since the subjects were people with diabetes, these hypoglycemia adverse events were anticipated and not related to the device. Also, all adverse events were mild.</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jane Wallace</name_or_title>
      <organization>Ascensia Diabetes Care</organization>
      <phone>574-257-3063</phone>
      <email>jane.wallace@ascensia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
